CHMP vouches for Ascendis Pharma's growth hormone for children
Ascendis Pharma is one step closer to launching its first drug in the EU, the growth hormone Skytrofa, as the EMA's expert committee, the CHMP, has given its positive recommendation for the treatment for children.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Children and adolescents aged 3 to 18 years old with growth hormone deficiency (GHD) should be able receive treatment with Ascendis Pharma's growth hormone Skytrofa, says the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis launches growth hormone Skytrofa in the US
For subscribers
